Taj Worldwide | Taj Group | Media | Career | FAQs | Feedback | contact us
Taj Logo
business sales top banner
Quality Medicines Api Generic Manufacturing For Doctors Brands Newsroom
   HOME >> Figure & Reports >> Business Sales

Business Sales





You can browse the Annual Report via an Interactive Version, download the entire report as a PDF-file, or view the individual chapters by clicking below.
  Financial report for FY 2011 (IFRS, audited) (PDF, 1416Kb)
  Financial report for FY 2010 (IFRS, audited) (PDF, 868Kb)
  Financial report for FY 2009 (IFRS, audited) (PDF, 1243Kb)
  Financial report for FY 2008 (IFRS, audited) (PDF, 1376Kb)
  Financial report for FY 2007 (IFRS, audited) (PDF, 1128Kb)
  Financial report for FY 2006 (IFRS, audited) (PDF, 791Kb)
  Financial report for FY 2005 (IFRS, audited) (PDF, 761Kb)
  Financial report for FY 2004 (IFRS, audited) (PDF, 727Kb)
  Annual Report 2011  (PDF, 5295Kb)
  Annual Report 2010 (PDF, 868Kb)
  Annual Report 2009 (PDF, 1243Kb)
  Annual Report 2008 (PDF, 1376Kb)
  Annual Report 2007 (PDF, 1128Kb)
  Annual Report 2006 (PDF, 791Kb)
  Annual Report 2005 (PDF, 761Kb)
  Annual Report 2004 (PDF, 727Kb)
Note: Taj Pharmaceuticals Limited (the "Company") believes that the information included in the Investor Relations section of this website was correct at the time it was added to the website. However, the Company expressly disclaims any duty to update the information on the website and makes no representation or warranty as to accuracy and completeness of the contents of this Investors Relations section of the website or any other section of the website. Access to and use of the information on this website is at the user's own risk. The Company assumes no responsibility for any errors or omissions in the content of this website and disclaims any liability for damages of any kind (whether direct, consequential or punitive) arising out of the use of this website or the information contained on the website or on links to or from this website.

The Investor Relations section of this website contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. All statements other than statements of historical facts, included on this website regarding the Company's strategy, expected future financial position, results of operations, cash flows, financing plans, discovery and development of products, strategic alliances, competitive position, plans and objectives of management are forward-looking statements. Words such as "anticipate," "believe," "estimate," "expect," "intend," "plan," "will" and other similar expressions help identify forward-looking statements, although not all forward-looking statements contain these identifying words. In particular, any statements regarding the Company's financial results and outlook, the continued implementation of the Company's strategic plan, the development of the Company's pipeline, the commencement of Phase 3 clinical trials for Puricase (pegloticase) are forward-looking statements. These forward-looking statements involve substantial risks and uncertainties and are based on current expectations, assumptions, estimates and projections about the Company's business and the biopharmaceutical and specialty pharmaceutical industries in which the Company operates. Such risks and uncertainties include, but are not limited to, the delay or failure in developing Puricase (pegloticase) and other product candidates; difficulties of expanding the Company's product portfolio through in-licensing or acquisition; not being able to manufacture commercial quantities of our products; not gaining market acceptance sufficient to justify development and commercialization costs if our products are approved for marketing; introduction of generic competition for API; fluctuations in buying patterns of wholesalers; potential future returns of API or other products; the Company continuing to incur substantial net losses for the foreseeable future; difficulties in obtaining financing; potential development of alternative technologies or more effective products by competitors; reliance on third-parties to manufacture, market and distribute many of the Company's products; risks of maintaining protection for the Company's intellectual property; risks of an adverse determination in any future intellectual property litigation; and risks associated with stringent government regulation of the biopharmaceutical and specialty pharmaceutical industries and other factors set forth more fully in certain reports filed with the Securities and Exchange Commission, to which investors are referred for further information. The Company may not actually achieve the plans, intentions or expectations disclosed in its forward-looking statements, and you should not place undue reliance on the Company's forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that the Company makes. The Company's forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments that the Company may make. The Company does not have a policy of updating or revising forward-looking statements and assumes no obligation to update any forward-looking statements.

Growing Stronger, Growing

Business sale

 Print page   Send by mail
















  india flag
  The Taj Pharmaceuticals Limited (Taj Group) has operations in every major international market





















About Taj


Products Diseases Health Divisions Media R & D Sustainability
Figure & Reports Investors


Brochure E-mail us Export & Import
Vacancies | C & F Agency | Distributor | Group Companies | History | Enquire Form | Countries | Pharma Technology
 Contact | Sitemap | User Terms and Conditions | Privacy and Cookie Statement